AJR Join ARRS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patterson, S. A.
Right arrow Articles by Panicek, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patterson, S. A.
Right arrow Articles by Panicek, D. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
DOI:10.2214/AJR.04.1030
AJR 2006; 187:307-312
© American Roentgen Ray Society


Original Research

MRI Evaluation of Small Hepatic Lesions in Women with Breast Cancer

Stacey A. Patterson1,2, Hanan I. Khalil1,3 and David M. Panicek1

1 Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.
2 Present address: Department of Radiology, Mount Sinai Hospital of Queens, Queens, NY.
3 Present address: Department of Diagnostic Imaging, Brown University and Rhode Island Hospital, Providence, RI.

Received June 29, 2004; accepted after revision May 29, 2005.

 
Presented at the 2005 annual meeting of the American Roentgen Ray Society, New Orleans, LA.

Address correspondence to D. M. Panicek (panicekd{at}mskcc.org).


Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
OBJECTIVE. The purpose of this study was to assess the utility of MRI in differentiating benign and malignant causes of hepatic lesions deemed too small to characterize on CT in women with breast cancer.

MATERIALS AND METHODS. A list of all women with breast cancer diagnosed between January 2000 and June 2003 was cross-referenced with radiologic and medical records to identify patients who had undergone MRI of the liver and who had had a hepatic lesion too small to characterize reported on previous CT performed after the diagnosis of breast cancer. The cause reported at MRI for each hepatic lesion too small to characterize seen on CT was recorded as benign, malignant, indeterminate, or no lesion seen on MRI. Subsequent relevant imaging examinations and medical records were reviewed.

RESULTS. Seventy-six (1.4%) of 5,440 women underwent MRI that included the liver. In 38 (50%) of the women a hepatic lesion too small to characterize was found on CT performed before MRI. The reported MRI diagnoses of hepatic lesions too small to characterize on CT included benign lesions (n = 22 women), lesions that remained indeterminate (n = 11 women), no lesion seen on MRI corresponding to the site of a lesion too small to characterize on CT (n = 8 women), and metastatic lesions (n = 2 women). Four women had more than one reported type of hepatic lesion. Subsequent findings of imaging, biopsy, or both performed on eight of 11 women with indeterminate lesions supported benign diagnoses in all eight women.

CONCLUSION. In women with newly diagnosed breast cancer and no definite liver metastasis on initial CT, immediate further evaluation of hepatic lesions too small to characterize with MRI offers only marginal benefit. In only approximately 5% of such women will lesions too small to characterize be shown on MRI to represent metastasis.

Keywords: breast cancer • CT • liver • MRI


Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
At the time of initial diagnosis of primary breast cancer and during subsequent routine follow-up evaluations, women with higher-stage tumors often undergo cross-sectional imaging for assessment of the extent of disease. At our institution, this evaluation typically includes CT of the chest, abdomen, and pelvis. Hepatic lesions are often detected, but because of their small size (typically 1.5 cm or smaller) and nonspecific imaging features on initial CT, these lesions often are deemed too small to characterize by the interpreting radiologist [1-3]. Further characterization is desirable, because the presence of hepatic metastasis may substantially alter prognosis and therapy [4].

MRI has been shown to effectively allow radiologists to differentiate with moderate to good interobserver agreement benign and malignant hepatic lesions 2 cm or smaller in patients with indeterminate findings on CT [5]. MRI is often ordered by clinicians for further characterization of hepatic lesions considered too small to characterize by our radiologists, but the utility of the information obtained from evaluation of such small lesions in patients with known breast cancer is unclear. We undertook this study to assess the value of hepatic MRI for differentiating benign and malignant causes of hepatic lesions too small to characterize detected on CT in patients with breast cancer.


Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
This retrospective study was approved by our institutional review board, which waived the need for informed consent.

Patients
The tumor registry at our institution, a dedicated cancer center, was searched for all women with the diagnosis of breast cancer made between January 2000 and June 2003. The resulting list was cross-referenced with our radiology information system to identify all women who had undergone abdominal MRI evaluation after the initial diagnosis of breast cancer. The radiologic and medical records for this subset of women were examined to identify women who had had hepatic lesions too small to characterize detected on CT performed before MRI and after the diagnosis of breast cancer.

Data Collection
The time interval between initial diagnosis of breast cancer and CT examination and the interval between CT and subsequent MRI examination were recorded. The CT scans and subsequent MR images and the associated official radiology reports were reviewed to classify the reported MRI results for each hepatic lesion too small to characterize as benign (e.g., cyst, hemangioma, focal nodular hyperplasia, focal fat), malignant, or of indeterminate cause. For each hepatic lesion too small to characterize deemed to be of indeterminate cause on the first MRI evaluation, the results of subsequent imaging evaluations and any biopsy of the lesion were recorded. The data were analyzed on a per-patient basis and on the basis of the number of lesion diagnoses reported on MRI for each patient. For example, a patient with four cysts was recorded as having one lesion diagnosis (i.e., cyst), and a patient with two hemangiomas and one cyst was recorded as having two hepatic lesion diagnoses (hemangioma and cyst). The official radiology reports and clinical records were reviewed for assessment of the presence of extrahepatic metastasis.

Imaging Technique
All MRI examinations were performed at our institution on 1.5-T scanners according to various protocols that included at least axial in-phase and opposed-phase T1-weighted gradient-echo images; axial fat-saturated fast spin-echo T2-weighted images; coronal single-shot fast spin-echo T2-weighted images; and dynamic multiphase gadolinium-enhanced axial T1-weighted gradient-echo images. Axial images were acquired at 7-mm slice thickness and coronal images at 8-mm thickness. Most of the CT examinations were performed at our institution on MDCT scanners at 7.0- or 7.5-mm collimation. Scans were obtained during the portal venous phase after power injection of 150 mL of IV contrast material.


Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Seventy-six (1.4%) of 5,440 women with breast cancer underwent MRI of the abdomen at or after the initial diagnosis of breast cancer. The reasons for MRI as recorded in the clinical statement portion of the official MRI report included assessment of hepatic lesion or lesions of any size identified on a previous imaging study (n = 59 [78%]), breast cancer staging (n = 7 [9%]), and other (n = 10 [13%]).

Thirty-eight (50%) of the 76 women had at least one hepatic lesion reported as too small to characterize on previous CT. The records of women with hepatic lesions not deemed too small to characterize on CT and women with hepatic lesions detected only on previous sonographic examinations were not analyzed further in this study. The mean time interval between initial diagnosis of breast cancer and CT for the 38 women was 28.8 weeks (range, 0-149 weeks). The mean time interval between CT and subsequent MRI was 4.9 weeks (range, 0-30 weeks). The mean age at diagnosis of breast cancer for these 38 women was 51.0 years (range, 29.9-73.6 years). At the time of diagnosis, breast cancer was pathologic stage I in 12 (32%) of the women, stage IIA in 10 (26%), stage IIB in 10 (26%), stage IIIA in 2 (5%), stage IIIB in 2 (5%), stage IIIC in 1 (3%), and stage IV in 1 (3%). Histologic types of breast cancer included infiltrating ductal carcinoma (n = 27 [71%]), lobular carcinoma with infiltrating ductal carcinoma or ductal carcinoma in situ (n = 7 [18%]), lobular carcinoma not otherwise specified (n = 2 [5%]), mucinous adenocarcinoma (n = 1 [3%]), and carcinoma not otherwise specified (n = 1 [3%]).

Hepatic Lesions Too Small to Characterize
One hepatic lesion too small to characterize was reported on CT in 15 (39%) of the women and more than one in 23 (61%). The specific diagnoses of hepatic lesions too small to characterize reported on MRI included cyst (n = 19 women) (Figs. 1A, 1B, 2A, and 2B), hemangioma (n = 5 women) (Figs. 2A and 2B), and metastasis (n = 2 women) (Figs. 3A and 3B). In 11 (30%) of the women, the hepatic lesions too small to characterize on CT remained of indeterminate cause on MRI. In eight (21%) of the women, no lesion was found on MRI at the site corresponding to at least one of the hepatic lesions too small to characterize on CT. Of these eight women, three also had a cyst, hemangioma, or indeterminate lesion on MRI corresponding to a hepatic lesion too small to characterize on CT, and five had no hepatic lesion on MRI corresponding to any of the hepatic lesions found on CT. Four patients had more than one type of hepatic lesion on MRI.


Figure 1
View larger version (132K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1A 71-year-old woman with invasive ductal carcinoma. Contrast-enhanced CT shows hepatic lesion (arrow) deemed too small to characterize.

 

Figure 2
View larger version (171K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1B 71-year-old woman with invasive ductal carcinoma. Contrast-enhanced T1-weighted MR image obtained 13 days after A shows lesion (large arrow) in A is not enhanced, diagnostic of cyst. Lesion (small arrow) in posterior right lobe represents partial volume averaging of another cyst, which was evident in more caudal images (not shown).

 

Figure 3
View larger version (156K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2A 54-year-old woman with ductal carcinoma in situ. Contrast-enhanced CT scan shows left hepatic lobe lesion (large arrow) deemed too small to characterize. Lesion (small arrow) in right hepatic lobe represents cyst, better seen in more caudal images (not shown).

 

Figure 4
View larger version (115K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2B 54-year-old woman with ductal carcinoma in situ. Contrast-enhanced T1-weighted MR image obtained 2 days later shows left hepatic lesion (arrow) with peripheral nodular enhancement. Lesion showed homogeneous, moderately high signal on T2-weighted images (not shown). Findings were considered diagnostic of hemangioma.

 

Figure 5
View larger version (110K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3A 41-year-old woman with inflammatory invasive ductal carcinoma. Contrast-enhanced CT scan shows low-attenuation hepatic lesion (arrow) deemed too small to characterize.

 

Figure 6
View larger version (101K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 3B 41-year-old woman with inflammatory invasive ductal carcinoma. Contrast-enhanced T1-weighted MR image obtained 10 days after A shows irregular peripheral enhancement in lesion (arrow). Lesion was only mildly hyperintense on T2-weighted images (not shown), consistent with metastasis. Results of fine-needle aspiration biopsy confirmed metastasis of breast cancer.

 
Of the 11 women with indeterminate hepatic lesions on MRI, follow-up CT or MRI was performed on six women, biopsy on one woman, and both imaging and biopsy on one woman. The mean interval to follow-up imaging for these eight women was 60.6 weeks (range, 17.1-136 weeks). On follow-up imaging, indeterminate hepatic lesions were unchanged in size (n = 5 women) or no longer visible (n = 2 women). Neither of the two women with lesions no longer visible was receiving chemotherapy during the interval to follow-up imaging. Histopathologic examination of the fine-needle aspiration specimens from two women revealed benign hepatocytes in one and benign hepatocytes with focal fatty change in the other. No malignant cells were present in either specimen.

Extrahepatic Metastasis
Extrahepatic metastatic lesions were present in 19 (50%) of the women. Eighteen of these women had axillary lymph node metastasis, and one had chest wall metastasis.


Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Hepatic lesions too small to characterize are a common finding on CT in women with newly diagnosed breast cancer. The reported incidence is at least one hepatic lesion too small to characterize in 29.4% of women without definite liver metastasis on CT [6]. However, liver metastasis is uncommon at initial diagnosis of breast cancer. Even among patients with metastatic breast cancer, the liver is not a common site of initial distant metastasis [4]. Samant and Ganguly [7] reported a low yield of routine liver imaging for hepatic metastasis in patients with newly diagnosed breast cancer without signs or symptoms suggestive of metastatic disease or abnormal results of routine blood tests. None of 250 patients in the study were found to have hepatic metastasis on the basis of results of liver imaging. Samant and Ganguly advised against liver imaging for patients with asymptomatic pathologically confirmed early stage (T1-2 N0-1) breast cancer. Likewise, because of the low incidence of liver metastasis, high cost, and false-positive findings (which occurred in 11.4% of 1,076 patients in their series), Gerber et al. [8] recommended abandonment of perioperative liver sonographic screening for metastatic disease in patients without clinical signs of tumor spread. Myers et al. [9] found very low detection rates of metastasis with liver sonography in patients with newly diagnosed breast cancer. Positive results were identified on liver sonography in no patients with pathologic stage I disease, 0.4% of patients with stage II disease, and 2.0% of patients with stage III disease. Myers et al. recommend that liver sonography not be performed on patients with newly diagnosed pathologic stage I or II breast cancer who have undergone surgical resection and who have no symptoms, signs, or biochemical evidence of metastasis. Postoperative liver sonography was recommended for patients with pathologic stage III disease as part of baseline scanning. Similarly, the clinical practice guidelines of the National Comprehensive Cancer Network for staging of breast cancer recommend abdominal CT, sonography, or MRI of the liver as optional examinations for stage IIA or IIB disease and consider them indicated for T3 N1 M0 disease or if alkaline phosphatase level or results of liver function tests are abnormal [10].

In addition to metastasis, diagnostic considerations for hepatic lesions too small to characterize on CT include cyst, hemangioma, and biliary hamartoma. Biliary hamartoma is a focal, disorderly collection of bile ducts. It is less frequently considered a diagnostic possibility on CT than are cyst and hemangioma but was reported in 2.8% of 707 consecutive autopsies [11]. Biliary hamartoma typically manifests as lesions smaller than 1 cm on CT that simulate cysts or metastatic lesions. The lesions are commonly multiple but can be solitary [12]. The appearance of biliary hamartomas on MRI has been described as hypointense on T1-weighted images and hyperintense on T2-weighted images with signal intensity similar to that of splenic tissue [13].

Hepatic lesions too small to characterize on CT may be further evaluated with sonography, dedicated CT, or MRI. Eberhardt et al. [14] reported that 66% of hepatic lesions were identified on focused sonograms performed with reference to a specific lesion on a preceding CT examination, whereas only 32% of hepatic lesions were detected without review of previous CT scans. Eberhardt et al. also found that on focused hepatic sonography, small hepatic lesions in 93% of women can be further characterized as cysts, solid or metastatic lesions, or hemangiomas.

Hollett et al. [15] reported improved detection of malignant hepatic neoplasms measuring 1.5 cm or less in 37% of patients on dual phase (arterial and portal venous phase) helical CT of the liver. Images acquired during the arterial phase of enhancement were more useful in evaluation of patients with hypervascular primary neoplasms. In accordance with the CT protocol for assessment for hepatic metastasis in breast cancer patients used at our institution during this study, one standard phase (i.e., portal venous phase) series was obtained on initial CT. It is possible that delayed imaging on initial CT may have helped to identify some hemangiomas. However, this retrospective study was not designed to determine the accuracy of CT in the characterization of small hepatic lesions.

In a study in which multiple logistic regression analysis was used to assess the importance of CT features such as lesion shape, margin sharpness, homogeneity, attenuation, and size among benign and malignant small hepatic lesions, the investigators [3] found that well-circumscribed lesions 5 mm or less in diameter were benign in 96% of cases. At our institution at the time of this study, the standard section thickness used for viewing images on a PACS workstation in a routine protocol to evaluate the extent of disease was 7.0 or 7.5 mm. Given that lesions measuring less than one half of the diameter of the section thickness are affected by partial volume averaging, lesions up to 1.5 cm in diameter may be difficult or impossible to characterize at 7.5-mm section thickness. In our study, thinner sections may have been useful on initial CT for evaluating some of the larger hepatic lesions too small to characterize, but because of less partial volume averaging with surrounding liver, thinner sections also probably contain even more hepatic lesions too small to characterize than do thicker sections.

Heavily T2-weighted fast spin-echo images and gadolinium contrast-enhanced MR images often allow characterization of even tiny lesions (e.g., less than 5 mm) as cysts, as has been shown with renal cysts [16]. In one study [5], MRI was shown to be an effective means of characterizing hepatic lesions less than 2 cm deemed indeterminate on CT as benign or malignant, both when interpreted in a routine clinical setting (area under the receiver operating characteristic curve [Az] = 0.94) and when interpreted by two expert reviewers (Az = 0.84 and 0.88). In contrast, our data suggest that MRI is of limited utility for evaluation of hepatic lesions deemed too small to characterize on CT of patients with known breast cancer. Explanations for the different conclusion of our study may be that all our patients had known cancer and that many of the hepatic lesions in our study were tiny, whereas only 27 of 48 patients in the other study had a history of cancer, and only 14 had lesions smaller than 1 cm.

In our study, hepatic lesions too small to characterize on MRI represented benign lesions alone or lesions that remained too small to characterize or of indeterminate cause in the large majority of the women. In only 5% of women with hepatic lesions too small to characterize were the lesions shown to be malignant on MRI. Thus in 95% of the women who underwent MRI evaluation of hepatic lesions too small to characterize on CT, the results of MRI did not alter medical management because therapy is not changed for benign or indeterminate liver lesions. Advances in CT and MRI technology allow use of thinner sections and thereby allow detection of ever smaller hepatic lesions. However, substantial limitations in characterization of such small hepatic lesions persist. The high prevalence of benign lesions in our study is supported by the findings of Khalil et al. [6], who reported that hepatic lesions too small to characterize on initial CT after diagnosis of breast cancer represent benign entities in 92.7-96.9% of women without other definite metastatic lesions of the liver. Similarly, hepatic lesions measuring 1 cm or less on CT were benign in 82% of 2,978 patients with cancer in a study by Schwartz et al. [2]. Jones et al. [1] reported that among 51% of 209 patients with cancer, hepatic lesions measuring less than 1.5 cm on CT were probably benign. The higher prevalence of benign lesions in our study may be related to our use of more advanced CT scanners with resultant differences in contrast timing, motion, and lesion conspicuity.

Noone et al. [17] found that 11 (32%) of 34 patients with newly diagnosed breast cancer who underwent MRI for suspected breast cancer metastasis had only benign liver lesions. Twenty-one other patients had malignant liver lesions: 19 had metastasis from breast cancer, one had metastasis from carcinoid tumor, and one had hepatocellular carcinoma. Those authors concluded that MRI is useful in the evaluation of breast cancer patients with clinically suspected liver metastasis at initial presentation. The much larger percentage of benign lesions in our study is at least partly explained by our inclusion of only hepatic lesions deemed too small to characterize on previous MRI. In the study by Noone et al., metastatic lesions measured up to 13 cm (mean, 1.5 cm). In addition, it is likely that different referring physicians have different thresholds for ordering abdominal MRI in this clinical context.

Hepatic lesions found on imaging to have decreased in size or disappeared may represent treated metastatic rather than benign lesions [3]. In our study, neither of the two women with hepatic lesions too small to characterize not visible on follow-up imaging was undergoing chemotherapy. Treated hepatic metastatic lesions of breast cancer have been reported in some cases to mimic hemangiomas on MRI [18]. One of five women with hemangiomas in our study underwent chemotherapy until 10 weeks before MRI. The hepatic lesion too small to characterize reported as hemangioma on MRI in this patient conceivably could have represented a treated metastatic lesion, further decreasing the utility of MRI in the evaluation of hepatic lesions too small to characterize in this patient population. The other four women with hemangiomas diagnosed on MRI in our study were not undergoing chemotherapy.

This retrospective study had several limitations. Only a small fraction of women with newly diagnosed breast cancer underwent MRI. The result was marked selection bias. However, MRI is typically requested by clinicians for only women believed on clinical grounds to be at moderate or high risk of hepatic metastasis. The small fraction of women who underwent MRI merely reflects our actual clinical practice. The study was not designed to assess the accuracy of CT or MRI in the detection or characterization of hepatic lesions too small to characterize but rather to assess our actual clinical practice at a dedicated oncology center. The sizes of the hepatic lesions too small to characterize were not mentioned in most cases in the official reports. As with all imaging findings, interobserver and intraobserver variability exist for reporting hepatic lesions too small to characterize on CT. This study was not designed to assess that variability. At our institution, we do not routinely monitor each CT scan, nor do we immediately repeat scans of patients with hepatic lesions too small to characterize at imaging. Such maneuvers might have decreased the number of hepatic lesions deemed too small to characterize. No tissue diagnosis was available for the majority of the small hepatic lesions in this study, as this represented actual clinical practice.

Radiologists ideally would be able to characterize every hepatic lesion too small to characterize. Unfortunately, many of these hepatic lesions remain uncharacterized, and the clinician must make decisions on the basis of available information. We undertook this study and another study of 1,012 women with breast cancer who underwent contrast-enhanced CT including the liver [6] to provide clinicians with an informed estimate of the likelihood of malignancy of hepatic lesions too small to characterize on CT and with help in evaluating these lesions. Hepatic lesions too small to characterize often are found on CT in women with newly diagnosed breast cancer. Given that the overwhelming majority of such lesions are benign in women without obvious liver metastasis, immediate further evaluation with MRI offers marginal benefit beyond peace of mind in cases in which a benign diagnosis can be made. Our findings, in conjunction with the high cost and limited availability of MRI and in accordance with the clinical practice guidelines of the National Comprehensive Cancer Network, led us to conclude that MRI is not warranted in the evaluation of hepatic lesions too small to characterize in every woman with newly diagnosed breast cancer.


Acknowledgments
 
We thank Chinyere Onyebuchi for assistance in data handling and analysis.


References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 

  1. Jones EC, Chezmar JL, Nelson RC, Bernardino ME. The frequency and significance of small hepatic lesions (less than or equal to 15 mm) detected by CT. AJR 1992;158 : 535-539[Abstract/Free Full Text]
  2. Schwartz LH, Gandras EJ, Colangelo SM, Ercolani MC, Panicek DM. Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology 1999;210 : 71-74[Abstract/Free Full Text]
  3. Robinson PJ, Arnold P, Wilson D. Small "indeterminate" lesions on CT of the liver: a follow-up study of stability. Br J Radiol 2003; 76:866 -874[Abstract/Free Full Text]
  4. Atalay G, Biganzoli L, Renard F, et al. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 2003;39 : 2439-2449[CrossRef][Medline]
  5. Mueller GC, Hussein HK, Carlos RC, Nghiem HV, Francis IR. Effectiveness of MR imaging in characterizing small hepatic lesions: routine versus expert interpretation. AJR 2003;180 : 673-680[Abstract/Free Full Text]
  6. Khalil HI, Patterson SA, Panicek DM. Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer. Radiology 2005;235 : 872-878[Abstract/Free Full Text]
  7. Samant R, Ganguly P. Staging investigations in patients with breast cancer: the role of bone scans and liver imaging. Arch Surg 1999; 134:551 -553[Abstract/Free Full Text]
  8. Gerber B, Seitz E, Muller H, et al. Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread. Breast Cancer Res Treat 2003; 82:29 -37[CrossRef][Medline]
  9. Myers RE, Johnston M, Pritchard K, Levine M, Oliver M. Baseline staging tests in primary breast cancer: a practice guideline. Can Med Assoc J 2001; 164:1439 -1444[Abstract/Free Full Text]
  10. Breast cancer. NCCN Clinical Practice Guidelines in Oncology, version 1.2005. Available at: www.nccn.org. Accessed April 10, 2005
  11. Thommesen N. Biliary hamartomas (von Meyenburg complexes) in liver needle biopsies. Acta Pathol Microbiol Immunol Scan [A] 1978; 86:93 -99
  12. Lev-Toaff AS, Bach AM, Wechsler RJ, Hilpert PL, Gatalica Z, Rubin R. The radiologic and pathologic spectrum of biliary hamartomas. AJR 1995; 165:309 -313[Abstract/Free Full Text]
  13. Sloane HW, Bennett WF, Bova JG. MR findings of multiple biliary hamartomas. AJR 1993;161 : 581-583[Free Full Text]
  14. Eberhardt SC, Choi PH, Bach AM, Funt SA, Felderman HE, Hann LE. Utility of sonography for small hepatic lesions found on computed tomography in women with cancer. J Ultrasound Med2003; 22:335 -343[Abstract/Free Full Text]
  15. Hollett MD, Jeffrey RB, Nino-Murcia M, Jorgensen MJ, Harris DP. Dual-phase helical CT of the liver: value of arterial phase scans in the detection of small (< or = 1.5 cm) malignant hepatic neoplasms. AJR 1995; 164:879 -884[Abstract/Free Full Text]
  16. Nascimento AB, Mitchell DG, Zhang XM, Kamishima T, Parker L, Holland GA. Rapid MR imaging detection of renal cysts: age-based standards. Radiology 2001;221 : 628-632[Abstract/Free Full Text]
  17. Noone TC, Semelka RC, Balci NC, Graham ML. Common occurrence of benign hepatic lesions in patients with newly diagnosed breast cancer investigated by MRI for suspected liver metastases. J Magn Reson Imaging 1999; 10:165 -169[CrossRef][Medline]
  18. Semelka RC, Worawattanakul S, Noone TC, et al. Chemotherapy-treated liver metastases mimicking hemangiomas on MR images. Abdom Imaging 1999; 24:378 -382[CrossRef][Medline]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patterson, S. A.
Right arrow Articles by Panicek, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patterson, S. A.
Right arrow Articles by Panicek, D. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS